Actuate Therapeutics

About:

Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.

Website: https://actuatetherapeutics.com

Top Investors: Tech Coast Angels, Kairos Ventures, DEFTA Partners, Bios Partners

Description:

Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3β. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.